As BlockDAG delays and Bitcoin Hyper stalls, investors flock to LivLive ($LIVE), a $2M AR-powered presale at $0.02 offering 12.5x ROI and real-world token rewards.As BlockDAG delays and Bitcoin Hyper stalls, investors flock to LivLive ($LIVE), a $2M AR-powered presale at $0.02 offering 12.5x ROI and real-world token rewards.

Investors Leave BlockDAG and Bitcoin Hyper for LivLive’s $2M Presale at $0.02 – Is This the Next Big Crypto?

2025/10/14 20:42
green-chart main

Crypto investors are rapidly shifting gears. While BlockDAG delays its long-awaited Genesis launch and Bitcoin Hyper continues to float without an exchange debut, a new name has entered the spotlight – LivLive, a blockchain-powered, augmented reality ecosystem that’s turning heads with over $2 million raised in its presale.

LivLive

With its token, $LIVE, priced at just $0.02 in Stage 1, LivLive is being hailed by early adopters as the next big crypto that blends real-world engagement with digital earning. The project has drawn attention from both tech and crypto communities, offering a unique mix of AR quests, tokenized experiences, and treasure vault rewards that make it stand out from the usual presale frenzy.

As traditional projects lose investor patience, LivLive has become the new frontier – a presale where participation feels more like joining a movement than buying a coin.

LivLive ($LIVE): Turning Real-World Action into Tokenized Value

LivLive has started its journey with unmatched momentum, already surpassing $2 million in presale funds and attracting 70+ early participants in its opening stage. The project runs on Ethereum (ERC-20), with a total supply of 5 billion $LIVE tokens, and an impressive 65% allocation dedicated to the community through presale, mining rewards, and real-world quests.

At its core, LivLive transforms real-world actions into economic value. Every movement, review, and referral within its AR-powered network is verified through blockchain, converting physical engagement into $LIVE rewards. This proof-of-presence mechanism ensures that every interaction is authentic, giving brands and users alike a tangible reason to participate.

Beyond tokenization, LivLive’s ecosystem features an exclusive wearable wristband that authenticates physical presence and unlocks AR experiences in real-time environments. From scanning stores to completing city-wide challenges, users can earn, level up, and unlock rewards through immersive gameplay that bridges digital and physical worlds.

LivLive 35753 1

A Treasure Vault That Could Change Lives

One of LivLive’s most exciting presale features is its $2.5 million Treasure Vault, where every token and NFT pack purchase includes a unique NFT key. Each key grants entry into multiple prize draws held throughout the presale, leading up to a grand $1 million ICON prize.

For investors, this isn’t just another lottery – it’s a mechanism that builds excitement, engagement, and real incentive to participate early. By purchasing through LivLive website and completing the Gleam actions, users unlock entries for every stage of the presale. With over 300 winners expected across various draw cycles, the odds of winning are enticingly higher than most token giveaways in the crypto space.

This blend of gamified investment and real-world reward is what’s driving investors away from passive presales and toward something interactive – a presale that feels alive, not static.

ROI Potential: From $0.02 to $0.25 – The Math Behind the Hype

With Stage 1 tokens priced at $0.02 and the launch price expected at $0.25, LivLive offers an early-stage multiplier that’s hard to ignore. That’s a 12.5x ROI for investors who join now – and even before considering bonuses.

Using the promo code EARLY30, buyers get 30% more tokens instantly. For instance, a $5,000 investment at $0.02 secures 250,000 $LIVE tokens, but with the EARLY30 bonus, that rises to 325,000 tokens. When $LIVE reaches its expected $0.25 launch price, that holding could be worth $81,250 – a potential 16x return.

This is why LivLive is being discussed as the next big crypto – not just for its concept, but for the math that makes sense to investors chasing both innovation and profit.

Referral Power: Earn as You Build

LivLive’s referral engine is another early-game changer. Every presale pioneer receives a unique referral link that can be shared with friends or followers. When someone buys through that link, both parties benefit – the referrer earns 10%, and the new buyer earns 5%.

This structure not only rewards community growth but also strengthens in-game ranking and future mining power, tying financial gain directly to ecosystem expansion. It’s a rare presale where referrals aren’t just marketing – they’re gameplay.

BlockDAG: Promises vs. Patience

Meanwhile, BlockDAG has faced its own turbulence. Touted as a hybrid Proof-of-Work and DAG-based blockchain designed to solve scalability issues, the project missed its August 11th launch and pushed back to November 23rd, leaving investors waiting longer than expected.

While the idea behind BlockDAG – merging security with speed – remains promising, the delayed rollout has frustrated many early backers. The project’s prolonged presale and lack of real market activity have caused some investors to reallocate toward faster-moving opportunities like LivLive’s ongoing presale.

Bitcoin Hyper: Ambition Without Access

Bitcoin Hyper (HYPER) takes an ambitious approach by building a Layer-2 smart contract solution for Bitcoin, aiming to power DeFi apps and meme coins through the BTC network. However, with no centralized exchange listing and no official TGE date, accessibility remains a key hurdle.

Investors intrigued by its concept are stuck waiting for liquidity and confirmation. In contrast, LivLive offers immediate participation, live rewards, and clear timelines – qualities that matter most in a market hungry for progress.

LivLive

The Final Word: LivLive Is Leading the New Wave

Based on current data and market sentiment, LivLive is emerging as the next big crypto with one of the most active and engaging presales of 2025. Its fusion of AR, blockchain, and gamified engagement has already captured the attention of early adopters, and with the presale still in Stage 1, the entry price remains a bargain.

Analysts suggest that once the $LIVE presale progresses to higher stages – climbing toward the $0.20 mark – ROI potential will shrink dramatically. Early participants not only benefit from the 30% EARLY30 bonus, but also from the lower price floor and active giveaway cycles through the Treasure Vault.

For investors looking beyond delays and uncertainty, LivLive represents the best blend of utility, innovation, and profitability. As others stall, LivLive’s $2M presale stands out as the one project turning everyday actions into extraordinary opportunity – and quite possibly, the next big crypto the world has been waiting for.

Find Out More Information Here:

Website: http://www.livlive.com 

X: https://x.com/livliveapp  

Telegram Chat: https://t.me/livliveapp

This article is not intended as financial advice. Educational purposes only.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Share Insights

You May Also Like

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million

The post New Viral Presale on XRPL: DeXRP Surpassed $6.4 Million  appeared on BitcoinEthereumNews.com. One of the most talked-about ecosystems in the cryptocurrency space is the XRP Ledger (XRPL), and DeXRP, the first Presale on XRPL, recently made headlines for its growth story. Attracting over 9,300 investors globally, the project has now raised over $6.4 million and is rapidly emerging as one of the most viral cryptocurrency launches of 2025. By integrating AMM and Order Book trading with a cutting-edge LP system and an open voting process for holders, DeXRP hopes to establish itself as the preferred trading destination for the XRPL community. What is DeXRP?  As the first decentralized exchange (DEX) based on XRPL, DeXRP is taking center stage as XRP continues to solidify its place in the global market. Massive expectation has been generated by the combination of DeXRP’s ambition for an advanced trading platform and XRPL’s established infrastructure, which is renowned for its quick transactions, cheap fees, and institutional-ready capabilities. In contrast to a lot of speculative presales, DeXRP’s development shows both institutional interest and community-driven momentum. Its early achievement of the $6.4 million milestone demonstrates how rapidly investors are realizing its potential. DeXRP Presale Success More than 9,300 distinct wallets have already joined the DeXRP presale, indicating a high level of interest from around the world. A crucial aspect is highlighted by the volume and variety of participation: DeXRP is not merely a niche project; rather, it is emerging as a major force in the XRPL ecosystem. DeXRP’s recent collaborations with WOW Earn and Micro3, as well as its sponsorship of the WOW Summit in Hong Kong, are also contributing factors to this uptick in investor confidence. These actions are blatant attempts to increase the company’s awareness among institutional players and crypto-native groups. The Forbes article summed it up: DeXRP is embedding credibility where others chase hype, marking it as…
Share
2025/09/18 20:14
Share
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
2025/09/18 05:26
Share